Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2022 | Developing the next generation of CAR-T cells

Yan Chen • 11 Apr 2022
AACR 2022
General CAR-T

Yan Chen, MD, PhD, Elpis Biopharmaceuticals, Boston, MA, outlines the development of bispecific chimeric antigen receptor T-cell (CAR-T) therapies that simultaneously target two tumor antigens. Bispecific CAR-T cells can overcome the resistance related to pre-treatment with targeted therapy or CAR-T cell therapy. These next-generation CAR-T cells are primarily being developed to treat patients who are relapsed or resistant to current CD19 CAR-T cell therapies. Clinical trials shall be undertaken to validate the effectiveness of bispecific CAR-T cell approaches. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.

More from Yan Chen

1:45
Research into multispecific and multifunctional cell therapy products
Yan Chen • 11 Apr 2022
3:38
Insights into EPIM-001 for the treatment of hematological malignancies
Yan Chen • 11 Apr 2022
2:01
Managing cytokine release syndrome during CAR-T cell therapy
Yan Chen • 11 Apr 2022
2:12
Fully human anti-CD19 and CD22 bispecific tandem CAR-T
Yan Chen • 11 Apr 2022

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals